{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:19:59Z","timestamp":1794277199974,"version":"4.9.0"},"reference-count":46,"publisher":"American Association for Cancer Research (AACR)","issue":"15","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although systemic androgen deprivation prolongs life in advanced prostate cancer, remissions are temporary because patients almost uniformly progress to a state of a castration-resistant prostate cancer (CRPC) as indicated by recurring PSA. This complex process of progression does not seem to be stochastic as the timing and phenotype are highly predictable, including the observation that most androgen-regulated genes are reactivated despite castrate levels of serum androgens. Recent evidence indicates that intraprostatic levels of androgens remain moderately high following systemic androgen deprivation therapy, whereas the androgen receptor (AR) remains functional, and silencing the AR expression following castration suppresses tumor growth and blocks the expression of genes known to be regulated by androgens. From these observations, we hypothesized that CRPC progression is not independent of androgen-driven activity and that androgens may be synthesized de novo in CRPC tumors leading to AR activation. Using the LNCaP xenograft model, we showed that tumor androgens increase during CRPC progression in correlation to PSA up-regulation. We show here that all enzymes necessary for androgen synthesis are expressed in prostate cancer tumors and some seem to be up-regulated during CRPC progression. Using an ex vivo radiotracing assays coupled to high-performance liquid chromatography-radiometric\/mass spectrometry detection, we show that tumor explants isolated from CRPC progression are capable of de novo conversion of [14C]acetic acid to dihydrotestosterone and uptake of [3H]progesterone allows detection of the production of six other steroids upstream of dihydrotestosterone. This evidence suggests that de novo androgen synthesis may be a driving mechanism leading to CRPC progression following castration. [Cancer Res 2008;68(15):6407\u201315]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-5997","type":"journal-article","created":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T13:58:13Z","timestamp":1217599093000},"page":"6407-6415","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":630,"title":["Androgen Levels Increase by Intratumoral\n                    <i>De novo<\/i>\n                    Steroidogenesis during Progression of Castration-Resistant Prostate Cancer"],"prefix":"10.1158","volume":"68","author":[{"given":"Jennifer A.","family":"Locke","sequence":"first","affiliation":[{"name":"1Department of Urologic Sciences, University of British Columbia, The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma S.","family":"Guns","sequence":"additional","affiliation":[{"name":"1Department of Urologic Sciences, University of British Columbia, The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy A.","family":"Lubik","sequence":"additional","affiliation":[{"name":"1Department of Urologic Sciences, University of British Columbia, The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada; and"},{"name":"2Institute of Health and Biomedical Innovation, Queensland University of Technology Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans H.","family":"Adomat","sequence":"additional","affiliation":[{"name":"1Department of Urologic Sciences, University of British Columbia, The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Hendy","sequence":"additional","affiliation":[{"name":"1Department of Urologic Sciences, University of British Columbia, The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Wood","sequence":"additional","affiliation":[{"name":"1Department of Urologic Sciences, University of British Columbia, The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Ettinger","sequence":"additional","affiliation":[{"name":"1Department of Urologic Sciences, University of British Columbia, The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.","family":"Gleave","sequence":"additional","affiliation":[{"name":"1Department of Urologic Sciences, University of British Columbia, The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen C.","family":"Nelson","sequence":"additional","affiliation":[{"name":"1Department of Urologic Sciences, University of British Columbia, The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada; and"},{"name":"2Institute of Health and Biomedical Innovation, Queensland University of Technology Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,8,1]]},"reference":[{"key":"2022061700311317000_B1","doi-asserted-by":"crossref","unstructured":"Goldenberg SL, Gleave ME, Taylor D, Bruchovsky N. Clinical experience with intermittent androgen suppression in prostate cancer: minimum of 3 years' follow-up. Mol Urol\u20081999; 3: 287\u201392.","DOI":"10.1097\/00005392-199904020-00202"},{"key":"2022061700311317000_B2","doi-asserted-by":"crossref","unstructured":"Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol\u20082005; 23: 8253\u201361.","DOI":"10.1200\/JCO.2005.03.4777"},{"key":"2022061700311317000_B3","doi-asserted-by":"crossref","unstructured":"Isaacs JT. The biology of hormone refractory prostate cancer. why does it develop? Urol Clin North Am\u20081999; 26: 263\u201373.","DOI":"10.1016\/S0094-0143(05)70066-5"},{"key":"2022061700311317000_B4","doi-asserted-by":"crossref","unstructured":"Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, et al. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate\u20082004; 59: 337\u201349.","DOI":"10.1002\/pros.20023"},{"key":"2022061700311317000_B5","doi-asserted-by":"crossref","unstructured":"Fedoruk MN, Gimenez-Bonafe P, Guns ES, Mayer Lawrence D, Nelson CC. P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate\u20082004; 59: 77\u201390.","DOI":"10.1002\/pros.10354"},{"key":"2022061700311317000_B6","unstructured":"Gleave M, Tolcher A, Miyake H, et al. Progression to androgen independence is delayed by adjuvant treatment with antisense bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res\u20081999; 5: 2891\u20138."},{"key":"2022061700311317000_B7","doi-asserted-by":"crossref","unstructured":"Rocchi P, So A, Kojima S, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res\u20082004; 64: 6595\u2013602.","DOI":"10.1158\/0008-5472.CAN-03-3998"},{"key":"2022061700311317000_B8","doi-asserted-by":"crossref","unstructured":"Rocchi P, Beraldi E, Ettinger S, et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res\u20082005; 65: 11083\u201393.","DOI":"10.1158\/0008-5472.CAN-05-1840"},{"key":"2022061700311317000_B9","doi-asserted-by":"crossref","unstructured":"Culig Z. Androgen receptor cross-talk with cell signaling pathways. Growth Factors\u20082004; 22: 179\u201384.","DOI":"10.1080\/08977190412331279908"},{"key":"2022061700311317000_B10","doi-asserted-by":"crossref","unstructured":"Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2\/neu tyrosine kinase. Nat Med\u20081999; 5: 280\u20135.","DOI":"10.1038\/6495"},{"key":"2022061700311317000_B11","doi-asserted-by":"crossref","unstructured":"Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3\u2032-kinase pathway. Endocrinology\u20082000; 141: 2257\u201365.","DOI":"10.1210\/endo.141.6.7520"},{"key":"2022061700311317000_B12","doi-asserted-by":"crossref","unstructured":"So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol\u20082005; 23: 1\u20139.","DOI":"10.1007\/s00345-004-0473-1"},{"key":"2022061700311317000_B13","doi-asserted-by":"crossref","unstructured":"Huang W, Shostak Y, Tarr P, Sawyers C, Carey M. Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J Biol Chem\u20081999; 274: 25756\u201368.","DOI":"10.1074\/jbc.274.36.25756"},{"key":"2022061700311317000_B14","doi-asserted-by":"crossref","unstructured":"Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res\u20082007; 67: 5033\u201341.","DOI":"10.1158\/0008-5472.CAN-06-3332"},{"key":"2022061700311317000_B15","doi-asserted-by":"crossref","unstructured":"Ettinger SL, Sobel R, Whitmore TG, et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res\u20082004; 64: 2212\u201321.","DOI":"10.1158\/0008-5472.CAN-2148-2"},{"key":"2022061700311317000_B16","doi-asserted-by":"crossref","unstructured":"Culig Z, Bartsch G. Androgen axis in prostate cancer. J Cell Biochem\u20082006; 99: 373\u201381.","DOI":"10.1002\/jcb.20898"},{"key":"2022061700311317000_B17","doi-asserted-by":"crossref","unstructured":"Singh P, Uzgare A, Litvinov I, Denmeade SR, Isaacs JT. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr Relat Cancer\u20082006; 13: 653\u201366.","DOI":"10.1677\/erc.1.00797"},{"key":"2022061700311317000_B18","doi-asserted-by":"crossref","unstructured":"Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer\u20082007; 120: 719\u201333.","DOI":"10.1002\/ijc.22365"},{"key":"2022061700311317000_B19","doi-asserted-by":"crossref","unstructured":"Titus Mark A, Schell Michael J, Lih Fred B, Tomer Kenneth B, Mohler James L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Hum Cancer Biol\u20082005; 11: 4653\u20137.","DOI":"10.1158\/1078-0432.CCR-05-0525"},{"key":"2022061700311317000_B20","doi-asserted-by":"crossref","unstructured":"Mohler JL, Gregory CW, Ford OH III, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res\u20082004; 10: 440\u20138.","DOI":"10.1158\/1078-0432.CCR-1146-03"},{"key":"2022061700311317000_B21","doi-asserted-by":"crossref","unstructured":"Han G, Buchanan G, Ittmann M, et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A\u20082005; 102: 1151\u20136.","DOI":"10.1073\/pnas.0408925102"},{"key":"2022061700311317000_B22","doi-asserted-by":"crossref","unstructured":"Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem\u20082006; 99: 333\u201344.","DOI":"10.1002\/jcb.20794"},{"key":"2022061700311317000_B23","doi-asserted-by":"crossref","unstructured":"Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res\u20082006; 66: 2815\u201325.","DOI":"10.1158\/0008-5472.CAN-05-4000"},{"key":"2022061700311317000_B24","doi-asserted-by":"crossref","unstructured":"Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer\u20082002; 95: 361\u201376.","DOI":"10.1002\/cncr.10647"},{"key":"2022061700311317000_B25","doi-asserted-by":"crossref","unstructured":"Small EJ, Ryan CJ. The case for secondary hormonal therapies in the chemotherapy age. J Urol\u20082006; 176: S66\u201371.","DOI":"10.1016\/j.juro.2006.06.071"},{"key":"2022061700311317000_B26","doi-asserted-by":"crossref","unstructured":"Liu J, Geller J, Albert J, Kirshner M. Acute effects of testicular and adrenal cortical blockade on protein synthesis and dihydrotestosterone content of human prostate tissue. J Clin Endocrinol Metab\u20081985; 61: 129\u201333.","DOI":"10.1210\/jcem-61-1-129"},{"key":"2022061700311317000_B27","doi-asserted-by":"crossref","unstructured":"Labrie F. Adrenal androgens and intracrinology. Semin Reprod Med\u20082004; 22: 299\u2013309.","DOI":"10.1055\/s-2004-861547"},{"key":"2022061700311317000_B28","doi-asserted-by":"crossref","unstructured":"Titus MA, Gregory CW, Ford OH III, Schell MJ, Maygarden SJ, Mohler JL. Steroid 5\u03b1-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res\u20082005; 11: 4365\u201371.","DOI":"10.1158\/1078-0432.CCR-04-0738"},{"key":"2022061700311317000_B29","unstructured":"Gregory CW, Hamil KG, Kim D, et al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res\u20081998; 58: 5718\u201324."},{"key":"2022061700311317000_B30","doi-asserted-by":"crossref","unstructured":"Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med\u20082004; 10: 33\u20139.","DOI":"10.1038\/nm972"},{"key":"2022061700311317000_B31","doi-asserted-by":"crossref","unstructured":"Swinnen JV, Heemers H, van de Sande T, et al. Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol\u20082004; 92: 273\u20139.","DOI":"10.1016\/j.jsbmb.2004.10.013"},{"key":"2022061700311317000_B32","doi-asserted-by":"crossref","unstructured":"Papadopoulos V, Amri H, Boujrad N, et al. Peripheral benzodiazepine receptor in cholesterol transport and steroidogenesis. Steroids\u20081997; 62: 21\u20138.","DOI":"10.1016\/S0039-128X(96)00154-7"},{"key":"2022061700311317000_B33","doi-asserted-by":"crossref","unstructured":"Auchus RJ. The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab\u20082004; 15: 432\u20138.","DOI":"10.1016\/S1043-2760(04)00214-0"},{"key":"2022061700311317000_B34","unstructured":"Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res\u20081992; 52: 1598\u2013605."},{"key":"2022061700311317000_B35","doi-asserted-by":"crossref","unstructured":"Yanase T, Gondo S, Okabe T, et al. Differentiation and regeneration of adrenal tissues: an initial step toward regeneration therapy for steroid insufficiency. Endocr J\u20082006; 53: 449\u201359.","DOI":"10.1507\/endocrj.KR-74"},{"key":"2022061700311317000_B36","doi-asserted-by":"crossref","unstructured":"Hales DB, Sha LL, Payne AH. Testosterone inhibits cAMP-induced de novo synthesis of Leydig cell cytochrome P-450(17\u03b1) by an androgen receptor-mediated mechanism. J Biol Chem\u20081987; 262: 11200\u20136.","DOI":"10.1016\/S0021-9258(18)60944-5"},{"key":"2022061700311317000_B37","unstructured":"Gregory CW, Johnson RT, Jr., Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res\u20082001; 61: 2892\u20138."},{"key":"2022061700311317000_B38","doi-asserted-by":"crossref","unstructured":"Kyprianou N, Isaacs JT. Biological significance of measurable androgen levels in the rat ventral prostate following castration. Prostate\u20081987; 10: 313\u201324.","DOI":"10.1002\/pros.2990100405"},{"key":"2022061700311317000_B39","doi-asserted-by":"crossref","unstructured":"Swinnen JV, Van Veldhoven PP, Esquenet M, Heyns W, Verhoeven G. Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology\u20081996; 137: 4468\u201374.","DOI":"10.1210\/endo.137.10.8828509"},{"key":"2022061700311317000_B40","doi-asserted-by":"crossref","unstructured":"van Weerden WM, Bierings HG, van Steenbrugge GJ, de Jong FH, Schroder FH. Adrenal glands of mouse and rat do not synthesize androgens. Life Sci\u20081992; 50: 857\u201361.","DOI":"10.1016\/0024-3205(92)90204-3"},{"key":"2022061700311317000_B41","doi-asserted-by":"crossref","unstructured":"Keeney DS, Jenkins CM, Waterman MR. Developmentally regulated expression of adrenal 17 \u03b1-hydroxylase cytochrome P450 in the mouse embryo. Endocrinology\u20081995; 136: 4872\u20139.","DOI":"10.1210\/endo.136.11.7588219"},{"key":"2022061700311317000_B42","doi-asserted-by":"crossref","unstructured":"Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev\u20082004; 25: 947\u201370.","DOI":"10.1210\/er.2003-0030"},{"key":"2022061700311317000_B43","doi-asserted-by":"crossref","unstructured":"Hu MC, Hsu HJ, Guo IC, Chung BC. Function of Cyp11a1 in animal models. Mol Cell Endocrinol\u20082004; 215: 95\u2013100.","DOI":"10.1016\/j.mce.2003.11.024"},{"key":"2022061700311317000_B44","doi-asserted-by":"crossref","unstructured":"Arakane F, Kallen CB, Watari H, et al. The mechanism of action of steroidogenic acute regulatory protein (StAR). StAR acts on the outside of mitochondria to stimulate steroidogenesis. J Biol Chem\u20081998; 273: 16339\u201345.","DOI":"10.1074\/jbc.273.26.16339"},{"key":"2022061700311317000_B45","doi-asserted-by":"crossref","unstructured":"Acevedo HF, Goldzieher JW. The metabolism of [4-14C] progesterone by hypertrophic and carcinomatous human prostate tissue. Biochim Biophys Acta\u20081965; 111: 294\u20138.","DOI":"10.1016\/0304-4165(65)90495-2"},{"key":"2022061700311317000_B46","doi-asserted-by":"crossref","unstructured":"Huang HTD. The role of the androgen receptor in prostate cancer. Crit Rev Eukaryot Gene Expr\u20082002; 12: 193\u2013207.","DOI":"10.1615\/CritRevEukaryotGeneExpr.v12.i3.30"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/15\/6407\/2594752\/6407.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/15\/6407\/2594752\/6407.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T01:54:04Z","timestamp":1655430844000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/15\/6407\/540963\/Androgen-Levels-Increase-by-Intratumoral-De-novo"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,1]]},"references-count":46,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2008,8,1]]},"published-print":{"date-parts":[[2008,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-5997","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1127021.584150","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,1]]}}}